Chemical-based primary human hepatocyte monolayer culture for the study of drug metabolism and hepatotoxicity: Comparison with the spheroid model
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhong, Yixiang | - |
dc.contributor.author | Yu, Jun Sang | - |
dc.contributor.author | Wang, Xiaoqiong | - |
dc.contributor.author | Binas, Bert | - |
dc.contributor.author | Yoo, Hye Hyun | - |
dc.date.accessioned | 2021-06-22T04:25:41Z | - |
dc.date.available | 2021-06-22T04:25:41Z | - |
dc.date.issued | 2021-03 | - |
dc.identifier.issn | 0892-6638 | - |
dc.identifier.issn | 1530-6860 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/442 | - |
dc.description.abstract | Traditionally cultured monolayers of primary human hepatocytes (PHHs) deteriorate within days and thereby become unsuitable for drug-related studies. PHH spheroids (3D PHHs) maintain liver functions for weeks, but are considerably more demanding. Recently, a chemical-based approach (5C PHHs) succeeded in long-term culture of hepatocyte monolayers, but it remains unclear whether the drug-related functions are preserved. To clarify this, we compared the 5C and 3D PHHs in terms of gene expression analysis, proteomic analysis, functionality (basal and induced activities of representative CYP450 enzymes and urea and albumin secretions), survival in culture, and sensitivity to representative drugs. In all comparisons, which spanned culture durations of up to 4 weeks, the 5C PHHs performed at least as well as the 3D PHHs. Hence, the novel 5C PHH monolayer format combines the convenience of the traditional monolayer format with the functionality and maintainability of the spheroid format. Our results suggest that 5C PHH monolayers can be used more conveniently and efficiently for high-throughput drug screening, preclinical drug safety evaluations, and mechanistic studies. | - |
dc.format.extent | 14 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Federation of American Societies for Experimental Biology | - |
dc.title | Chemical-based primary human hepatocyte monolayer culture for the study of drug metabolism and hepatotoxicity: Comparison with the spheroid model | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1096/fj.202001629RR | - |
dc.identifier.scopusid | 2-s2.0-85101446335 | - |
dc.identifier.wosid | 000629576700025 | - |
dc.identifier.bibliographicCitation | FASEB Journal, v.35, no.3, pp 1 - 14 | - |
dc.citation.title | FASEB Journal | - |
dc.citation.volume | 35 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 14 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Life Sciences & Biomedicine - Other Topics | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordAuthor | drug induced liver injury | - |
dc.subject.keywordAuthor | drug metabolism | - |
dc.subject.keywordAuthor | hepatotoxicity | - |
dc.subject.keywordAuthor | long term cell culture | - |
dc.subject.keywordAuthor | primary human hepatocyte | - |
dc.identifier.url | https://faseb.onlinelibrary.wiley.com/doi/10.1096/fj.202001629RR | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.